Fibroblast Growth Factor Family As a Potential Target in the Treatment of Hepatocellular Carcinoma

Overview

Journal J Hepatocell Carcinoma

Date 2016 Aug 11

PMID 27508175

Citations 4

Authors

Stacey J Coleman

Richard P Grose

Hemant M Kocher

Affiliations

Soon will be listed here.

Abstract

Hepatocellular cancer (HCC) is currently the third leading cause of cancer death worldwide. The prognosis of patients diagnosed with late-stage disease is dismal due to high resistance to conventional systemic therapies. The introduction of sorafenib, despite its limited efficacy, as the standard systemic therapy for advanced HCC has paved a way for targeted molecular therapies for HCC. Fibroblast growth factor (FGF) signaling plays an important role in the developing embryo and the adult. The FGF signaling pathway is often hijacked by cancer cells, including HCC. Several alterations in FGF signaling correlate with poor outcome in HCC patients, suggesting that this family of signaling molecules plays an important role in the development of HCC. Multikinase inhibitors targeting FGF signaling are currently under investigation in clinical trials. This review discusses the current understanding of the biological and clinical implications of aberrant FGF signaling in the prognosis, diagnosis, and treatment of HCC.

Citing Articles

The Consumption of Cholesterol-Enriched Diets Conditions the Development of a Subtype of HCC with High Aggressiveness and Poor Prognosis.

Simoni-Nieves A, Salas-Silva S, Chavez-Rodriguez L, Escobedo-Calvario A, Desoteux M, Bucio L Cancers (Basel). 2021; 13(7).

PMID: 33917315 PMC: 8038696. DOI: 10.3390/cancers13071721.

Transcriptome profiles associated with selenium-deficiency-dependent oxidative stress identify potential diagnostic and therapeutic targets in liver cancer cells.

Gozen D, Kahraman D, Narci K, Shehwana H, Konu O, Cetin-Atalay R Turk J Biol. 2021; 45(2):149-161.

PMID: 33907497 PMC: 8068766. DOI: 10.3906/biy-2009-56.

Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma.

Paur J, Valler M, Sienel R, Taxauer K, Holzmann K, Marian B Liver Int. 2020; 40(9):2279-2290.

PMID: 32378800 PMC: 7496895. DOI: 10.1111/liv.14505.

Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression.

Joo Y, Jang J, Lee S, Yoo S, Kwon J, Nam S Sci Rep. 2019; 9(1):9137.

PMID: 31235729 PMC: 6591389. DOI: 10.1038/s41598-019-45537-w.

References

Cao H, Phan H, Yang L . Improved chemotherapy for hepatocellular carcinoma. Anticancer Res. 2012; 32(4):1379-86. View

Hughes S . Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem. 1997; 45(7):1005-19. DOI: 10.1177/002215549704500710. View

Casanovas O, Hicklin D, Bergers G, Hanahan D . Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8(4):299-309. DOI: 10.1016/j.ccr.2005.09.005. View

Llovet J, Decaens T, Raoul J, Boucher E, Kudo M, Chang C . Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013; 31(28):3509-16. DOI: 10.1200/JCO.2012.47.3009. View

Hu M, Qiu W, Wang Y, Hill D, Ring B, Scully S . FGF-18, a novel member of the fibroblast growth factor family, stimulates hepatic and intestinal proliferation. Mol Cell Biol. 1998; 18(10):6063-74. PMC: 109192. DOI: 10.1128/MCB.18.10.6063. View

Ebos J, Lee C, Cruz-Munoz W, Bjarnason G, Christensen J, Kerbel R . Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3):232-9. PMC: 4540346. DOI: 10.1016/j.ccr.2009.01.021. View

GOSPODAROWICZ D . Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature. 1974; 249(453):123-7. DOI: 10.1038/249123a0. View

. Hepatic induction in the avian embryo: specificity of reactive endoderm and inductive mesoderm. J Embryol Exp Morphol. 1981; 63:111-25. View

Kan M, Wu X, Wang F, McKeehan W . Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem. 1999; 274(22):15947-52. DOI: 10.1074/jbc.274.22.15947. View

10.

Wake K . "Sternzellen" in the liver: perisinusoidal cells with special reference to storage of vitamin A. Am J Anat. 1971; 132(4):429-62. DOI: 10.1002/aja.1001320404. View

11.

Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T . Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology. 2011; 53(3):854-64. DOI: 10.1002/hep.24099. View

12.

Ho H, Pok S, Streit S, Ruhe J, Hart S, Lim K . Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol. 2008; 50(1):118-27. DOI: 10.1016/j.jhep.2008.08.015. View

13.

Huang X, Godfrey T, Gooding W, McCarty Jr K, Gollin S . Comprehensive genome and transcriptome analysis of the 11q13 amplicon in human oral cancer and synteny to the 7F5 amplicon in murine oral carcinoma. Genes Chromosomes Cancer. 2006; 45(11):1058-69. DOI: 10.1002/gcc.20371. View

14.

French D, Lin B, Wang M, Adams C, Shek T, Hotzel K . Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One. 2012; 7(5):e36713. PMC: 3352934. DOI: 10.1371/journal.pone.0036713. View

15.

Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz G . A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol. 2002; 160(6):2295-307. PMC: 1850847. DOI: 10.1016/S0002-9440(10)61177-7. View

16.

Zhu X, Sasse J, McAllister D, Lough J . Evidence that fibroblast growth factors 1 and 4 participate in regulation of cardiogenesis. Dev Dyn. 1996; 207(4):429-38. DOI: 10.1002/(SICI)1097-0177(199612)207:4<429::AID-AJA7>3.0.CO;2-J. View

17.

Yamashita T, Budhu A, Forgues M, Wang X . Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007; 67(22):10831-9. DOI: 10.1158/0008-5472.CAN-07-0908. View

18.

Bosch F, Ribes J, Diaz M, Cleries R . Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004; 127(5 Suppl 1):S5-S16. DOI: 10.1053/j.gastro.2004.09.011. View

19.

Wiedemann M, Trueb B . Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors. Genomics. 2000; 69(2):275-9. DOI: 10.1006/geno.2000.6332. View

20.

Katoh M, Katoh M . Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol Ther. 2006; 5(9):1059-64. DOI: 10.4161/cbt.5.9.3151. View